WO1996038175A1 - Stabilized composition comprising an antiulcerative benzimidazole - Google Patents
Stabilized composition comprising an antiulcerative benzimidazole Download PDFInfo
- Publication number
- WO1996038175A1 WO1996038175A1 PCT/JP1996/001427 JP9601427W WO9638175A1 WO 1996038175 A1 WO1996038175 A1 WO 1996038175A1 JP 9601427 W JP9601427 W JP 9601427W WO 9638175 A1 WO9638175 A1 WO 9638175A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- composition according
- groups
- cyclodextrin
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 230000000767 anti-ulcer Effects 0.000 title claims abstract description 35
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title description 7
- -1 benzimidazole compound Chemical class 0.000 claims abstract description 116
- 229940126409 proton pump inhibitor Drugs 0.000 claims abstract description 8
- 239000000612 proton pump inhibitor Substances 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 125000003545 alkoxy group Chemical group 0.000 claims description 50
- 229920000858 Cyclodextrin Polymers 0.000 claims description 28
- 229960003174 lansoprazole Drugs 0.000 claims description 25
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 22
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 9
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 125000000962 organic group Chemical group 0.000 claims description 7
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 5
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 229960000381 omeprazole Drugs 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 229960003194 meglumine Drugs 0.000 claims description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 3
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims 3
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 55
- 150000001875 compounds Chemical class 0.000 description 41
- 239000000243 solution Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000843 powder Substances 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 9
- 150000002367 halogens Chemical group 0.000 description 9
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 9
- 150000001556 benzimidazoles Chemical class 0.000 description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 229940097362 cyclodextrins Drugs 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 239000008151 electrolyte solution Substances 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- SJCXTMZZGQRDQF-UHFFFAOYSA-N 5-(3,4-dihydroxyphenyl)-11-[(3,5-dihydroxyphenyl)methyl]-6,11-dihydro-5h-dibenzo[1,4-e:3',4'-f][7]annulene-2,3,8,10-tetrol Chemical compound OC1=CC(O)=CC(CC2C3=C(O)C=C(O)C=C3CC(C3=CC(O)=C(O)C=C32)C=2C=C(O)C(O)=CC=2)=C1 SJCXTMZZGQRDQF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- AJERVVHSERWGFL-UXBLZVDNSA-N (e)-1-[3-(2-hydroperoxy-3-methylbut-3-enyl)-2-hydroxy-4-methoxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound OC1=C(CC(OO)C(C)=C)C(OC)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 AJERVVHSERWGFL-UXBLZVDNSA-N 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 206010002243 Anastomotic ulcer Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- DYPZZHZYUZHEFW-UHFFFAOYSA-N Xanthoangelol E Natural products COc1ccc(C(=O)C=Cc2ccc(O)cc2)c(O)c1C(CC(=C)C)OO DYPZZHZYUZHEFW-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000002280 acid secreting cell Anatomy 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- OPLNDEGFDPLWPZ-UHFFFAOYSA-N ethyl 8-methoxy-4-(2-propan-2-ylanilino)quinoline-3-carboxylate Chemical compound CCOC(=O)C1=CN=C2C(OC)=CC=CC2=C1NC1=CC=CC=C1C(C)C OPLNDEGFDPLWPZ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229950007395 leminoprazole Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940080526 mannitol injection Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- XZENCZPCSRXPSL-UHFFFAOYSA-N n,6-dimethyl-1-(2-methylphenyl)-2,3-dihydropyrrolo[3,2-c]quinolin-4-amine Chemical compound C1CC=2C(NC)=NC3=C(C)C=CC=C3C=2N1C1=CC=CC=C1C XZENCZPCSRXPSL-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- IPAJARTUAXFVLF-UHFFFAOYSA-N sodium;9-(1h-benzimidazol-2-ylsulfinyl)-4-methoxy-2,5,6,7,8,9-hexahydrocyclohepta[b]pyridin-1-ide Chemical compound [Na+].COC1=CC[N-]C2=C1CCCCC2S(=O)C1=NC2=CC=CC=C2N1 IPAJARTUAXFVLF-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229950011585 timoprazole Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
Definitions
- the present invention relates to a stabilized composition containing an antiulcerative benzimidazole compound with enhanced water-solubility. Specifically, it relates to a stabilized composition containing an antiulcerative benzimidazole compound useful as medicaments or veterinary drugs, particularly antiulcerative agents, the stability of the composition and the water-solubility of the compound being enhanced by combining it with a branched cyclodextrin-carboxylic acid which is a cyclodextrin derivative.
- Cyclodextrins have been used as effective means to solve this problem. Cyclodextrins have been used for providing suitable volatility or improving taste or smell, or for emulsification, powdering or stabilization, as well as for enhancing solubility of medicaments, etc. It is believed that these effects of cyclodextrins are produced by the formation of complexes containing active ingredients of pharmaceutical compositions, etc., in the cyclodextrins.
- cyclodextrins Various homologs of such cyclodextrins are known. Their water solubilities vary with their kinds. For example, ⁇ -, ⁇ - and ⁇ -cyclodextrins consist of six, seven and eight glucose units, respectively, that are joined in such a way as to form a ring, and it is reported that the water-solubilities of ⁇ -, ⁇ - and ⁇ -cyclodextrins are about 15%, about 2% and about 23%, respectively.
- the present inventors have intensively studied how to enhance the water-solubility of antiulcerative benzimidazole compounds and the stability of the compositions containing the compounds. As a result, it has been found that use of a cyclodextrin having certain improved characteristics can achieve the above objects. Thus, the present invention has been completed.
- the present invention provides a stabilized composition comprising an antiulcerative benzimidazole compound and a branched cyclodextrin-carboxylic acid or a salt thereof.
- the present invention also provides a method of enhancing stability of a composition containing an antiulcerative benzimidazole compound, which comprises combining an antiulcerative benzimidazole compound with a branched cyclodextrin-carboxylic acid or a salt thereof.
- the present invention also provides a method of enhancing solubility in water of an antiulcerative benzimidazole compound, which comprises combining the antiulcerative benzimidazole compound with a branched cyclodextrin-carboxylic acid or a salt thereof.
- the antiulcerative benzimidazole compound is preferably a proton pump inhibitor, in particular lansoprazole or omeprazole.
- the composition further comprises a pH adjusting agent, preferably meglumine.
- the composition is preferably an injectable composition, and is preferably miscible with a transfusion solution.
- composition of the present invention is particularly stable in a solid form, in particular a lyophilized form.
- the branched cyclodextrin-carboxylic acid to be used in the present invention is intended to include its free carboxylic acid, and a salt thereof with an alkali metal (e.g., lithium, sodium, potassium, etc.), alkaline earth metal (e.g., calcium, magnesium, etc.), etc.
- alkali metal e.g., lithium, sodium, potassium, etc.
- alkaline earth metal e.g., calcium, magnesium, etc.
- the branched cyclodextrin-carboxylic acid is a cyclodextrin having an organic group containing at least one carboxyl group at the 6-0-position of at least one glucose unit of the cyclodextrin ring.
- the cyclodextrin ring in the branched cyclodextrin- carboxylic acid has, for example, 6, 7 or 8 glucose units.
- the cyclodextrin ring has 7 glucose units.
- Examples of the cyclodextrin include ⁇ -cyclodextrin, ⁇ - cyclodextrin and ⁇ -cyclodextrin. It is preferred that the organic group containing at least one carboxyl group has 1 to 3 glucose units, and that at least one of the hydroxymethyl groups of the glucose units in the organic group is oxidized to a carboxyl group.
- Examples of the branched cyclodextrin-carboxylic acidin include 6-0-cyclomaltohexaosyl-(6-l)- ⁇ -D-glucosyl-(4-l)- O- ⁇ -D-glucuronic acid (cyclomaltohexaosyl-(6-1)-0- ⁇ -D- glucopyranosyl-(4-1)-O- -D-glucopyranosiduronic acid) (hereinafter also abbreviated as c_-CyD-G 2 -C00H; the abbreviations of the following compounds are likewise shown in the parentheses), 6-0-cyclomaltoheptaosyl-(6-1)- -D- glucosyl-(4-l )-0- -D-glucuronic acid (cyclomaltoheptaosyl- ( 6-1 ) -O- ⁇ -D-glucopyranosyl- ( 4-1 ) -O- ⁇ -
- CyD-Gj-COOH 6-0-cyclomaltooctaosyl-( 6-1 ) - ⁇ -D-glucuronic acid ( cyclomaltooctaosyl- ( 6-1 ) -O- ⁇ -D-glucopyranosiduronicacid ) ( ⁇ - CyD-Gj-COOH) , 2-0- (6-cyclomaltohexaosyl) -acetic acid ( ⁇ -CyD- CH 2 C00H), 2-0- (6-cyclomaltoheptaosyl) -acetic acid ( ⁇ -CyD- CH 2 C00H), 2-0- (6-cyclomaltooctaosyl) -acetic acid ( ⁇ -CyD-
- 6-0-cyclomaltohexaosyl-(6-1)- ⁇ -D- glucosyl-(4-l)-0- ⁇ -D-glucuronic acid ⁇ -CyD-G 2 -COOH
- 6-0- cyclomaltoheptaosyl-(6-1)- ⁇ -D-glucosyl-(4-1)-O- ⁇ -D-glucuronic acid ⁇ -CyD-G 2 -C00H
- 6-0-cyclomaltooctaosyl-(6-1)- ⁇ -D- glucosyl-(4-1)-O- ⁇ -D-glucuronic acid ⁇ -CyD-G 2 -C00H
- branched cyclodextrin-carboxylic acids containing ⁇ - cyclodextrin (containing 6 glucose units), ⁇ -cyclodextrin (containing 7 glucose units) and ⁇ -cyclodextrin (containing 8 glucose units), respectively.
- maltose is attached to one of the glucose units of the cyclodextrin ring through an ⁇ -(l-6) linkage, and the hydroxymethyl group (-CH 2 0H) at the 6- position of the terminal glucose unit of the maltose is oxidized to a carboxyl group to give glucuronic acid.
- Eachof 6-0-cyclomaltohexaosyl-(6-1)- ⁇ -D-glucuronic acid ( ⁇ -CyD-G i -COOH) , 6-0-cyclomaltoheptaosyl-(6-l)- ⁇ -D- glucuronic acid ( ⁇ -CyD-G ⁇ COOH) and 6-O-cyclomaltooctaosyl- (6-1)- ⁇ -D-glucuronic acid ( ⁇ -CyD-G.-COOH) is a branched cyclodextrin-carboxylic acid in which glucose is attached to one of the glucose units of the cyclodextrin ring through an ⁇ -(l-6) linkage, and the hydroxymethyl group (-CH 2 0H) at the 6-position of the branched glucose is oxidized to a carboxyl group to give glucuronic acid.
- 2-0-(6-cyclomaltohexaosyl)-acetic acid ( ⁇ - CyD-CH 2 C00H)
- 2-0-(6-cyclomaltoheptaosyl)-acetic acid ( ⁇ -CyD- CH 2 C00H)
- 2-0-(6-cyclomaltooctaosyl)-acetic acid ( ⁇ -CyD- CH 2 C00H) are preferable branched cyclodextrin-carboxylic acid wherein a carboxymethyl group is attached as a branch to one of the glucose units of the cyclodextrin ring.
- the water-solubility of an antiulcerative benzimidazole compound and the stability of the compositions containing the compound can be enhanced by formulating the compound together with a branched cyclodextrin-carboxylic acid.
- the antiulcerative benzimidazole compound to be used is normally a proton pump inhibitor having a water-solubility of not more than 10 mg/ml.
- proton pump inhibitor as used herein is defined as a drug that suppresses acid secretion by directly or indirectly inhibiting H/K-ATPase, which functions as a proton pump in gastric mucosal acid secreting cells (parietal cells).
- Such drugs include omeprazole, lansoprazole, pantoprazole, pariprazole sodium, leminoprazole, TY-11345, TU-199, FPL-65372, BY-686, Tannic acid, Ellagic acid, Ebselen, AHR-9294, Cassigarol-A, Bafilomycin, Y-25942, Xanthoangelol E, SK&F-96356, (-)- Epigallocatechin gallate, Y-27198, T-330 and KF-20054.
- proton pump inhibitors include benzimidazole compounds, which possess proton pump inhibitory activities and are of low toxicity.
- benzimidazole compounds include 2-[ (pyridyl)-methylsulfinyl or methylthio]benzimidazole derivatives and salt thereof.
- a compound (or salt thereof) represented by formula (I) below is more preferred.
- R is a hydrogen atom, an alkyl group, an acyl group, a carboalkoxy group, a carbamoyl group, an alkylcarbamoyl group, a dialkylcarbamoyl group or an alkylsulfonyl group;
- R c , R ⁇ , and R 8 are, the same or different, a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkoxy group;
- R is a hydrogen atom, an alkyl group or a group represented by -OR in which R represents a hydrocarbon group which may optionally be substituted; q is 0 or 1.
- Benzimidazole compounds above are described in USP 4,045,563, USP 4,255,431, USP 4,359,465, USP 4,472,409, USP 4,508,905, USP 5,039,806 (JP-A 59181277), USP 4,628,098, USP 4,738,975, USP 5,045,321, USP 4,786,505, USP 4,853,230, USP 5,045,552, EP-A-295603, USP 5,312,824, EP-A-166287, EP-A- 519365, and other publications.
- the substituent that may optionally be present on ring A includes halogen atoms, alkyl groups which may be substituted for, cycloalkyl groups which may be substituted for, alkenyl groups which may be substituted for, alkoxy groups which may be substituted for, cyano groups, carboxy groups, carboalkoxy groups, carboalkoxyalkyl groups, carbamoyl groups, carbamoylalkyl groups, hydroxy groups, hydroxyalkyl groups, acyl groups, carba oyloxy groups, nitro groups, acyloxy groups, aryl groups, aryloxy groups, alkylthio groups and alkylsulfinyl groups, and the like.
- the above substituents are hereinafter described.
- Halogen atoms include fluorine, chlorine, bromine and iodine. Fluorine and chlorine are preferred, with greater preference given to fluorine.
- alkyl group in the alkyl group which may be substituted is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms (e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl) .
- straight-chain or branched alkyl groups having 1 to 10 carbon atoms e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, h
- Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms.
- Substituents on the substituted alkyl group include halogens, nitro, cyano groups, hydroxy groups, carboxy groups, amidino groups, guanidino groups, carbamoyl groups, amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.
- the cycloalkyl group in the cycloalkyl group which may be substituted is exemplified by cycloalkyl groups having 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, etc.
- the cycloalkyl group may be substituted by, for example, halogens, nitro, cyano groups, hydroxy groups, carboxy groups, amidino groups, guanidino groups, carbamoyl groups, amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.
- alkenyl group in the alkenyl group which may be substituted is exemplified by straight-chain or branched alkenyl groups having 2 to 16 carbon atoms.
- alkenyl groups include allyl, vinyl, crotyl, 2-penten-l-yl, 3-penten- 1-yl, 2-hexen-l-yl, 3-hexen-l-yl, 2-methyl-2-propen-l-yl and 3-methyl-2-buten-l-yl.
- Straight-chain or branched alkenyl groups having 2 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkenyl groups having 2 to 4 carbon atoms.
- the alkenyl group may be substituted by, for example, halogens, nitro, cyano groups, amidino groups, guanidino groups amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.
- the alkenyl group mentioned above includes isomers (E- and Z-configurations) with respect to double bond.
- the alkoxy group in the alkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 10 carbon atoms.
- alkoxy groups include methoxy, ethoxy, n- propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert- butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, cyclobutoxy, cyclopentoxy and cyclohexyloxy.
- Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.
- the alkoxy group may be substituted by, for example, halogens, nitro, amidino groups, guanidino groups amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like
- the halogen as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is exemplified by chlorine, bromine, fluorine and iodine.
- the alkyl group in the alkylamino group as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is preferably exemplified by straight-chain or branched alkyl groups having 1 to 6 carbon atoms.
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, isopentyl, n-hexyl and isohexyl.
- straight-chain or branched alkyl groups having 1 to 4 carbon atoms are preferred.
- acyl group in the acylamino group as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is exemplified by acyl groups derived from organic carboxylic acids, with preference given to alkanoyl groups having 1 to 6 carbon atoms.
- alkanoyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl, with greater preference given to alkanoyl groups having 1 to 4 carbon atoms.
- the number of substituents on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is 1 to 6, preferably 1 to 3.
- the substituted alkyl groups include trifluoro- ethyl, trifluoroethyl, difluoromethyl, trichloromethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyethyl, ethoxyethy, 1-methoxyethyl, 2-methoxyethyl, 2,2-dimethoxy- ethyl, 2,2-diethoxyethyl and 2-diethylphosphorylethyl, among others.
- Difluoromethyl, trifluoromethyl and hydroxymethyl are preferred, with greater preference given to trifluoromethyl.
- the substituted cycloalkyl groups include 2- aminocyclopropan-1-yl, 4-hydroxycyclopentan-l-yl and 2,2- difluorocyclopentan-1-yl, among others.
- the substituted alkenyl groups include 2,2- dichlorovinyl, 3-hydroxy-2-propen-l-yl and 2-methoxyvinyl, among others.
- the substituted alkoxy groups include difluoromethoxy, trifluoro ethoxy, 2,2,2-trifluoroethoxy, 2- methoxyethoxy, 4-chlorobenzyloxy and 2-(3,4-dimethoxypehnyl)- ethoxy, among others. Difluoromethoxy is preferred.
- the alkoxy group in the carboalkoxy group is exemplified by alkoxy groups having 1 to 7 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxyl, heptyloxy) .
- the alkoxy group in the carboalkoxyalkyl group is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy) .
- the alkyl group in the carboalkoxyalkyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl).
- Such carboalkoxyalkyl groups include carbomethoxymethyl, 2- carbomethoxyethyl, 2-carbomethoxypropyl, carboethoxymethyl, 2-carboethoxyethyl, 1-carbomethoxypropyl, carbopropoxymethyl and carbobutoxymethyl.
- the alkyl group in the carba oylalkyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert-butyl) .
- the alkyl group in the hydroxyalkyl group is exemplified by alkyl groups having 1 to 7 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl) .
- the acyl group as such or the acyl group in the acyloxy group is exemplified by alkanoyl groups having 1 to 4 carbon atoms such as formyl, acetyl, propionyl, butyryl and isobutyryl.
- the aryl group as such or the aryl group in the aryloxy group is exemplified by aryl groups having 6 to 12 carbon atoms (e.g., phenyl, naphthyl).
- the alkyl in the alkylthio group or alkylsulfinyl group is exemplified by alkyl groups having 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl) .
- the number of substituents on substituted ring A is preferably 1 to 4, more preferably 1 to 2. Such substituents on the benzene ring may be present at 4- and 5-positions, with preference given to 5- ⁇ osition.
- Ring A is preferably a ring which may optionally be substituted by i) a halogen atom, ii) an alkyl group which may be substituted, iii) a cycloalkyl group which may be substituted, iv) an alkenyl group which may be substituted, or v) an alkoxy group which may be substituted.
- the alkyl group for R b is exemplified by alkyl groups having 1 to 5 carbon atoms (e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl).
- the acyl group for R is exemplified by acyl groups having 1 to 4 carbon atoms, such as alkanoyl groups having 1 to 4 carbon atoms.
- the alkoxy in the carboalkoxy group is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., formyl, acetyl, propionyl, butyryl, isobutyryl).
- the alkyl in the alkylcarbamoyl group and dialkylcarbamoyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl).
- the alkyl in the alkylsulfonyl group is exemplified by the above-mentioned alkyl groups having 1 to 4 carbon atoms.
- R is preferably hydrogen.
- the alkyl group for R c , R ⁇ or R 8 is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms (e.g.
- the alkoxy group for R c , R e or R 8 is exemplified by alkoxy groups having 1 to 10 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec- butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy) .
- Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.
- the alkoxy in the alkoxyalkoxy group for R c , R e or R 8 is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy) .
- R c is preferably a hydrogen atom, an alkyl group or an alkoxy group.
- R ⁇ is preferably a hydrogen atom, an alkyl group or an alkoxy group.
- R 8 is preferably a hydrogen atom.
- the alkyl group for R d is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl).
- the hydrocarbon group in the hydrocarbon group which may optionally be substituted, for R f is exemplified by hydrocarbon groups having 1 to 13 carbon atoms, such as straight-chain or branched alkyl groups having 1 to 6 carbon atoms (e.g.
- alkenyl groups having 2 to 6 carbon atoms e.g., vinyl, allyl, 2-butenyl, methylallyl, 3-butenyl, 2-pentenyl, 4-pentenyl, 5-hexenyl
- alkynyl groups having 2 to 6 carbon atoms e.g., ethynyl, propargyl, 2-butyn-l-yl, 3-butyn-2-yl, l-pentyn-3-yl, 3- pentyn-1-yl, 4-pentyn-2-yl, 3-hexyn-l-yl)
- cycloalkyl groups having 3 to 6 carbon atoms e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclo
- Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 4 carbon atoms.
- the substituent group in the substituted hydrocarbon group is exemplified by C 6 _ 10 aryl groups (e.g., phenyl, naphthyl), amino, C j . ⁇ alkylamino groups (e.g., methylamino, ethylamino, isopropylamino) , di-Cj.g alkylamino groups (e.g., dimethylamino, diethylamino) , N-aralkyl-N-cycloalkylamino groups (e.g., N-benzyl-N-cyclohexylamino) , N-aralkyl-N- alkylamino groups (e.g., N-(1-naphthylmethyl)-N-ethylamino) , azide, nitro, halogens (e.g., fluorine, chlorine, bromine, iodine), hydroxyl, C ⁇ alkoxy groups (e
- alkoxycarbonyl groups e.g., methoxycarbonyl, ethoxycarbonyl
- C 7 _ u aryloxycarbonyl groups e.g., phenoxycarbonyl, 1-naphthyloxycarbonyl, 2-naphthyloxy- carbonyl
- carboxy-C ⁇ _ 4 alkoxy groups e.g., carboxymethoxy, 2-carboxyethoxy
- 6 alkanoyl groups e.g., formyl, acetyl, propionyl, isopropionyl, butyryl, pentanoyl, haxanoyl
- C 7 _ n alloyl groups e.g., benzoyl, 1-naphthoyl, 2-naphthoyl
- C 6 _ 10 arylsulfonyl groups e.g., benzenesulfonyl, 1-naphthyl- sulfonyl, 2-naphthylsulfonyl
- C ⁇ alkylsulfinyl groups e.g., methylsulfinyl, ethylsulfinyl
- C 6 _ 10 arylsulfinyl groups e.g., benzenesulfinyl, 1-naphthylsulfinyl, 2-naphth
- heterocyclic thio groups e.g., 4-pyridylthio, 2- pyrimidylthio, l,3,4-thiadiazol-2-ylthio, l-methyl-5- tetrazolylthio
- the heterocyclic thio group may condense with the benzene ring to form a bicyclic condensed thio group
- Halogens e.g., fluorine, chlorine, bromine, iodine
- hydroxyl and C ⁇ alkoxy groups e.g., methoxy, ethoxy, propoxy, butoxy
- the number of substituents is normally 1 to 5, preferably 1 to 3.
- R is preferably an alkoxy group which may be substituted, or an alkoxyalkoxy group which may be substituted.
- the alkoxy in the alkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 8 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy) .
- alkoxy in the alkoxyalkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy) .
- R is more preferably an alkoxy group having 1 to 8, preferably 1 to 4 carbon atoms, which may be halogenated, or an alkoxyalkoxy group which may be halogenated.
- Preferred alkoxy groups which may be halogenated include 2,2,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, 1-(trifluoromethyl)-2, 2, 2-trifluoroethox , 2,2,3,3- tetrafluoropropoxy, 2,2,3,3,4,4,4-heptafluorobutoxy, 2,2,3,3,4,4,5,5,-octafluoropentoxy and methoxy.
- Preferred alkoxyalkoxy groups which may be halogenated include 3- methoxypropoxy. q is preferably 0.
- benzimidazole compound for the present invention is exemplified by a compound represented by formula (II) :
- ring A may optionally be substituted;
- R , R and R are, the same or different, hydrogen, or an alkyl or alkoxy group;
- R 2 is a hydrocarbon group which may optionally be substituted;
- n is 0 or 1.
- ring A is exemplified by the same rings as those mentioned for ring A of formula (I) above.
- the alkyl group for R 1 , R 3 or R A is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms.
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl.
- Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms.
- the alkoxy group for R 1 , R 3 or R is exemplified by alkoxy groups having 1 to 10 carbon atoms.
- alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, cyclobutoxy, cyclopentoxy and cyclohexyloxy.
- Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.
- hydrocarbon group which may optionally be substituted, for R 2 is exemplified by the same hydrocarbon groups as those mentioned for R above.
- R 1 is preferably C ⁇ alkyl or C ⁇ alkoxy, more preferably C ⁇ .
- R is preferably hydrogen or C ⁇ alkyl, more preferably hydrogen.
- R is preferably C ⁇ alkoxy which may optionally be substituted by i) halogen, ii) hydroxyl or iii) alkoxy, more preferably, C ⁇ _ 3 alkyl which may optionally be substituted by i) halogen or ii) C w alkoxy.
- R is preferably hydrogen.
- benzimidazole compounds for the present invention include 2-[2-[3-methyl-4-(2,2,3,3-tetrafluoro- propoxy)pyridyl]methylthio]benzimidazole, 2-[2-[3-methyl-4- (2,2,2-trifluoroethoxy)pyridyl]methylsulfinyl]benzimidazole (lansoprazole) , 2-[ (2-pyridyl)methylsulfinyl]benzimidazole (timoprazole) , 2-[2-(3,5-dimethyl-4-methoxypyridyl)methyl- sulfinyl]-5-methoxy-lH-benzimidazole (omeprazole), sodium salt of 2-[2-[4-(3-methoxypropoxy)-3-methyl]pyridyl]methylsulfinyl- lH-benzimidazole and 2-[2-(3,4-dimethoxy)pyridyl]methyl-
- lansoprazole and omeprazole are preferably applied to the present invention.
- a benzimidazole compound (or salt thereof) for the present invention is produced by, for example, the above- described known methods described in Japanese or European Patent Publications and U.S. Patents, or modifications thereof.
- the salt of a benzimidazole compound is preferably used as a physiologically acceptable salt.
- Physiologically acceptable salts include salts with inorganic bases, salts with organic bases and salts with basic amino acids.
- Useful inorganic bases include alkali metals (e.g., sodium, potassium) and alkaline earth metals (e.g., calcium, magnesium).
- Useful organic bases include trimethylamine, triethylamine, pyridine, picoline, N,N-dibenzylethylene- diamine, ethanolamine, diethanolamine, trishydroxymethyl- aminomethane and dicyclohexylamine.
- Useful basic amino acids include arginine and lysine.
- the mixing ratio of the branched cyclodextrin-carboxylic acid to the antiulcerative benzimidazole compounds is not limited and can be selected from wide ranges.
- the amount of the branched cyclodextrin- carboxylic acid to be used is 0.1 to 20 mol, preferably 0.1 to 10 mol, more preferably 0.2 to 5 mol, particularly preferably 2 to 5 mol, per mol of the antiulcerative benzimidazole compound.
- composition of the present invention can be prepared by mixing the branched cyclodextrin-carboxylic acid with the antiulcerative benzimidazole compound according to known methods. Roughly speaking, the inclusion compound of the antiulcerative benzimidazole compound included in the branched cyclodextrin-carboxylic acid can be prepared, for example, by the following four methods:
- the inclusion compound can be prepared as follows: (1) A compound to be included in the inclusion compound is added to an aqueous solution of the branched cyclodextrin-carboxylic acid (hereinafter sometimes referred to as the cyclodextrin). The mixture is stirred (shaken), if necessary, under warming. The remaining unreacted compound to be included is removed by filtration, centrifugation, etc., to obtain an inclusion compound.
- the cyclodextrin branched cyclodextrin-carboxylic acid
- the cyclodextrin is dissolved in water, and a compound to be included is added thereto. The two are mixed for 10 minutes to several hours, followed by lyophilization (M. Kurozumi et al., Chem. Pharm. Bull., 23, 142 (1975)) to give powder. This powder is dissolved in water, and the unreacted compound to be included is removed to obtain an aqueous solution of an inclusion compound.
- a compound to be included is dissolved in an appropriate water-soluble organic solvent in advance. This solution is contacted with cyclodextrin in an aqueous solution.
- a compound to be included is dissolved in a lipophilic organic solvent (e.g., ethyl ether, etc.), and the solution is mixed with a saturated aqueous solution of the cyclodextrin. The mixture is shaken vigorously for 10 minutes to several hours and then allowed to stand in a cold place overnight to precipitate an inclusion compound. The precipitate is separated by centrifugation or filtration. The resulting powder is dissolved in water to give an aqueous solution of an inclusion compound.
- a lipophilic organic solvent e.g., ethyl ether, etc.
- a powdered compound to be included and powdered cyclodextrin are mixed, and a small amount of water is added thereto.
- the mixture is kneaded (Y. Nakai et al., Chem. Pharm. Bull., 26, 2419 (1978)) and then, if necessary, lyophilized.
- An aqueous solution of the cyclodextrin and an aqueous solution of a compound to be included are mixed to give an aqueous solution of an inclusion compound.
- the above method (3) is useful for solubilization of antiulcerative benzimidazole compounds.
- the aqueous solution or powder thus obtained by the known methods giving inclusion compounds contains an inclusion compound or a complex formed by electrostatic or hydrophobic interactions or hydrogen bonds, etc. Therefore, the term "inclusion compound” used in the present invention means not only an inclusion compound or a complex per se but also a mixture of an inclusion compound, a complex, a free compound to be included and/or a free cyclodextrin. That is, the powder and aqueous solution obtained may contain, other than an inclusion compound or a complex, a water-insoluble or slightly water-soluble compound that is not included or complexed, and/or free cyclodextrin.
- the inclusion compound per se and powder and an aqueous solution like this have extremely high water-solubilities and dissolve in water instantly.
- composition of the present invention may be the aqueous solution or powder per se thus obtained, or it may be a pharmaceutical composition in an appropriate dosage form, a veterinary composition, etc. , prepared using known additives such as excipients, binders or lubricants.
- saccharides for example, to improve properties of the powder obtained above (packing capacity into a storage bottle or a vial, specific volume, destaticizing, etc.), saccharides, antiseptics, stabilizers, antistatic agents, etc., can be added.
- the powder obtained by this operation readily dissolves in an aqueous isotonic solution prepared using distilled water or sodium chloride and saccharides (e.g., glucose, mannitol, inositol, etc.).
- the resulting injectable preparation containing an active ingredient can be administered intravenously, intramuscularly, subcutaneously, into organs, or directly to foci such as tumor or excised parts of tumor, in a drug concentration effective in vivo against the diseases to be treated.
- oral preparations tablets, capsules, granules, fine granules, enveloped preparations, drops, liquids, etc., can be prepared.
- known excipients, lubricants, binders, dispersers, stabilizers, colorants and absorption-improving (promoting) agents, etc. can normally be used.
- the above powder can also be formulated into preparations other than injectable or oral preparations according to conventional methods.
- preparations are preparations administered to mucous membranes such as nose, the rectum.
- Each of the above preparations can be molded into various controlled-release preparations or preparations for targeting therapies, and the composition of the present invention can be used as a raw material of such preparations.
- the composition is preferably an injectable composition, especially intravenously injectable solution.
- the composition preferably further contains a pH adjusting agent, such as meglumine, sodium hydroxide, potassium hydroxide, ammonia water, sodium bicarbonate, sodium carbonate, triethanolamine , monoethanolamine , diisopropanolamine, triisopropanolamine and L-arginine.
- the amount of the pH adjusting agent to be used is 0.01 to 10 mol, preferably 0.1 to 5 mol, per mol of the antiulcerative benzimidazole compound.
- the composition is miscible with a transfusion solution, and can be used as a mixture of the composition and a transfusion solution.
- transfusion solution examples include glucose injection, xylitol injection, D-mannitol injection, fructose injection, isotonic sodium chloride solution, dextran 40 injection, dextran 70 injection, amino acid injection, Ringer's injection, lactated Ringer's injection.
- the ratio of the composition to the transfusion solution is 1/1 (v/v) to 1/500 (v/v), preferably 1/20 (v/v) to 1/100 (v/v).
- the composition of the present invention is applicable to the prevention and treatment of animal ulcers, and is particularly effective in the prevention and treatment of digestive ulcers in mammals (e.g., humans, monkeys, cattle, dogs, swine, etc.).
- digestive ulcers include gastric ulcer, duodenal ulcer, reflux esophagitis, anastomotic ulcer, acute and chronic gastritis.
- compositions comprising lansoprazole as the antiulcerative benzimidazole compound can be used in accordance with the manner described in EP 0174726.
- the composition of the present invention can be administered in an appropriate dosage form such as injections, oralpreparations, syrups, preparations externally administered to skin, pernasal preparations, rectal suppositories or preparations applied to mucous membranes.
- compositions of the present invention are chosen as appropriate, according to ulcer type, symptoms, age and the other factors, for example, in the case of the compositions of proton pump inhibitors, the compositions are administered at the dose of 0.01 mg/kg/day -
- the daily dose of lansoprazole is 0.01 - 30 mg/kg, more preferably 0.1 - 3 mg/kg.
- lansoprazole alone was added to water. The mixture was shaken at room temperature, and filtered through a membrane filter (0.22 ⁇ m) . The lansoprazole in the above homogeneous aqueous solution and filtrate was determined by high performance liquid chromatography (HPLC) . HPLC conditions:
- the lyophilized composition comprising ⁇ -CyD-G 2 - COONa and lansoprazole of the present invention was an inclusion compound which was stable at room temperature without decomposition of the lansoprazole.
- Example 3
- Example 4 The lyophilized powder obtained in Example 3 was filled into vials (150 mg powder per vial) and dried over phosphorus pentaoxide, and each vial was sealed under an atmosphere of nitrogen gas. A preparative stability test was carried out at 40°C for 4 weeks. The water content was 0.5% after drying over phosphorus pentaoxide, and the amount of the residual lansoprazole was not less than 95% after 4 weeks.
- the lyophilized powder obtained in Example 3 was dissolved in water for injection (150 mg powder per ml of the water for injection).
- the solution was mixed with isotonic sodium chloride solution (Otsuka Seishoku Chu (Otsuka Pharmaceutical Co., Ltd.)), glucose injection (Ohtsuka Toeki 5% (Otsuka Pharmaceutical Co., Ltd.)), Ringer's solution containing low molecular weight dextran and lactic acid (Low Molecular Weight Dextran L Injection (Otsuka Pharmaceutical Co., Ltd.)) and an electrolyte solution for transfusion (Solita T No. 3 (Shimizu Pharmaceutical Co., Ltd.)).
- the stability of lansoprazole after the addition of transfusion solution was tested.
- composition ratio of the aqueous lyophilized powder solution to the transfusion solution was 1/99 (v/v) .
- the amount of the residual lansoprazole was not less than 98% in the isotonic sodium chloride solution and glucose injection until 8 hours after the addition, not less than 97% in the Ringer's solution until 4 hours after the addition, and not less than 93% in the electrolyte solution for transfusion until 4 hours after the addition.
- Example 3 The lyophilized powder obtained in Example 3 was dissolved in water for injection (150 mg powder per ml of the water for injection). The solution was added to each of Ringer's solution containing low molecular weight dextran and lactic acid (Low Molecular Weight Dextran L Injection (Otsuka Pharmaceutical Co., Ltd.)) and an electrolyte solution for transfusion (Solita T No. 3 (Shimizu Pharmaceutical Co., Ltd.)).
- Ringer's solution containing low molecular weight dextran and lactic acid Low Molecular Weight Dextran L Injection (Otsuka Pharmaceutical Co., Ltd.)
- an electrolyte solution for transfusion Solita T No. 3 (Shimizu Pharmaceutical Co., Ltd.)
- the stability of lansoprazole after the addition of the transfusion solution was compared with that in a formulation containing no cyclodextrin-carboxylic acid [the formulation being a solution of lyophilized powder of lansoprazole (30 mg) containing mannitol (60 mg) and meglu ine (10 mg) in an aqueous 30% polyethylene glycol 400 solution (5 rol)]- Tne composition ratio of the aqueous lyophilized powder solution to the transfusion solution was 1/99 (v/v) .
- the composition ratio of the formulation containing no cyclodextrin-carboxylic acid to the transfusion solution was 1/99 (v/v).
- the amounts of the lansoprazole remaining 1 hour, 4 hours and 18 hours after the addition of the electrolyte solution for transfusion were 98.2%, 93.3% and 62.3%, respectively, in the case of the composition of Example 3, compared with 60.1%, 12.8% and 0%, respectively, in the case of the formulation containing no cyclodextrin-carboxylic acid.
- the composition of the present invention is very stable, and the antiulcerative benzimidazole compound combined with a branched cyclodextrin-carboxylic acid according to the present invention has a much higher water- solubility compared with that of the antiulcerative benzimidazole compound alone.
- the branched cyclodextrin-carboxylic acid has less effect (e.g., destruction of erythrocytes) on the living body than ⁇ - cyclodextrin, and therefore is highly safe for blood.
- ⁇ -CyD-G 2 -COOH is hardly decomposed with acids or enzymes, and therefore the composition of the present invention is highly safe to mammals including humans.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A stabilized composition comprising an antiulcerative benzimidazole compound, particularly a proton pump inhibitor, and a branched cyclodextrin-carboxylic acid.
Description
STABILIZED COMPOSITION COMPRISING AN ANTIULCERATIVE BENZIMIDAZOLE
FIELD OF THE INVENTION
The present invention relates to a stabilized composition containing an antiulcerative benzimidazole compound with enhanced water-solubility. Specifically, it relates to a stabilized composition containing an antiulcerative benzimidazole compound useful as medicaments or veterinary drugs, particularly antiulcerative agents, the stability of the composition and the water-solubility of the compound being enhanced by combining it with a branched cyclodextrin-carboxylic acid which is a cyclodextrin derivative.
BACKGROUND OF THE INVENTION It is the most general and important problem in the field of pharmaceutics to enhance the water-solubility of water-insoluble or slightly water-soluble drugs and the stability of the composition containing the drugs. Cyclodextrins have been used as effective means to solve this problem. Cyclodextrins have been used for providing suitable volatility or improving taste or smell, or for emulsification,
powdering or stabilization, as well as for enhancing solubility of medicaments, etc. It is believed that these effects of cyclodextrins are produced by the formation of complexes containing active ingredients of pharmaceutical compositions, etc., in the cyclodextrins.
Various homologs of such cyclodextrins are known. Their water solubilities vary with their kinds. For example, α-, β- and γ-cyclodextrins consist of six, seven and eight glucose units, respectively, that are joined in such a way as to form a ring, and it is reported that the water-solubilities of α-, β- and γ-cyclodextrins are about 15%, about 2% and about 23%, respectively.
SUMMARY OF THE INVENTION
The present inventors have intensively studied how to enhance the water-solubility of antiulcerative benzimidazole compounds and the stability of the compositions containing the compounds. As a result, it has been found that use of a cyclodextrin having certain improved characteristics can achieve the above objects. Thus, the present invention has been completed.
The present invention provides a stabilized composition comprising an antiulcerative benzimidazole compound and a branched cyclodextrin-carboxylic acid or a salt thereof.
The present invention also provides a method of enhancing stability of a composition containing an antiulcerative benzimidazole compound, which comprises combining an antiulcerative benzimidazole compound with a branched cyclodextrin-carboxylic acid or a salt thereof.
The present invention also provides a method of enhancing solubility in water of an antiulcerative benzimidazole compound, which comprises combining the antiulcerative benzimidazole compound with a branched cyclodextrin-carboxylic acid or a salt thereof.
In the present invention, the antiulcerative benzimidazole compound is preferably a proton pump inhibitor, in particular lansoprazole or omeprazole. Preferably, the composition further comprises a pH adjusting agent, preferably meglumine. The composition is preferably an injectable composition, and is preferably miscible with a transfusion solution.
The composition of the present invention is particularly stable in a solid form, in particular a lyophilized form.
DETAILED DESCRIPTION OF THE INVENTION The branched cyclodextrin-carboxylic acid to be used in the present invention is intended to include its free carboxylic acid, and a salt thereof with an alkali metal
(e.g., lithium, sodium, potassium, etc.), alkaline earth metal (e.g., calcium, magnesium, etc.), etc. These branched cyclodextrin-carboxylic acids can be used alone or in combination thereof, or as mixtures of their free carboxylic acids and salts thereof.
The branched cyclodextrin-carboxylic acid is a cyclodextrin having an organic group containing at least one carboxyl group at the 6-0-position of at least one glucose unit of the cyclodextrin ring. The cyclodextrin ring in the branched cyclodextrin- carboxylic acid has, for example, 6, 7 or 8 glucose units. Preferably, the cyclodextrin ring has 7 glucose units. Examples of the cyclodextrin include α-cyclodextrin, β- cyclodextrin and γ-cyclodextrin. It is preferred that the organic group containing at least one carboxyl group has 1 to 3 glucose units, and that at least one of the hydroxymethyl groups of the glucose units in the organic group is oxidized to a carboxyl group.
Examples of the branched cyclodextrin-carboxylic acidinclude 6-0-cyclomaltohexaosyl-(6-l)-α-D-glucosyl-(4-l)- O-α-D-glucuronic acid (cyclomaltohexaosyl-(6-1)-0-α-D- glucopyranosyl-(4-1)-O- -D-glucopyranosiduronic acid) (hereinafter also abbreviated as c_-CyD-G2-C00H; the abbreviations of the following compounds are likewise shown in the parentheses), 6-0-cyclomaltoheptaosyl-(6-1)- -D-
glucosyl-(4-l )-0- -D-glucuronic acid (cyclomaltoheptaosyl- ( 6-1 ) -O-α-D-glucopyranosyl- ( 4-1 ) -O-α-D-glucopyranosiduronic acid) (β-CyD-G2-COOH) , 6-0-cyclomaltooctaosyl- ( 6-1 )-α-D- glucosyl-(4-l)-0- -D-glucuronic acid (cyclomaltooctaosyl- ( -1 ) -O-α-D-glucopyranosyl- ( 4 -1 ) -O-α-D-glucopyranosiduronic acid) (γ-CyD-G2-COOH) , 6-0-cyclomaltohexaosyl-( 6-1 )-α-D- glucuronic acid ( cyclomaltohexaosyl- ( 6-1 ) -O-α-D- glucopyranosiduronic acid ) (α-CyD-Gi-COOH ) , 6-0- cyclomaltoheptaosyl-( 6-1 )-α-D-glucuronic acid (cyclomaltoheptaosyl-( 6-1) -O-α-D-glucopyranosiduronic acid) (β-
CyD-Gj-COOH) , 6-0-cyclomaltooctaosyl-( 6-1 ) -α-D-glucuronic acid ( cyclomaltooctaosyl- ( 6-1 ) -O-α-D-glucopyranosiduronicacid ) ( γ- CyD-Gj-COOH) , 2-0- (6-cyclomaltohexaosyl) -acetic acid (α-CyD- CH2C00H), 2-0- (6-cyclomaltoheptaosyl) -acetic acid (β-CyD- CH2C00H), 2-0- (6-cyclomaltooctaosyl) -acetic acid (γ-CyD-
CH2C00H), 3-0-( 6-cyclomaltoheptaosyl)-propionic acid (β-CyD- CH2CH2COOH) , 2-hydroxy-3-0-(6-cyclomaltoheptaosyl)-propionic acid (3-0-(6-cyclomaltoheptaosyl)-2-hydroxy-propionic acid)(β- CyD-CH2CH(0H)-C00H) , 7A, 7c-di-0- [α-D-glucuronyl- ( 1-4 ) -O-α-D- glucosyl]-(l-6)-maltoheptaose ( β-CyD- (G2COOH)2) , 6-0- cyclomaltoheptaosyl-O-α-D-maltosyl- ( 4-1 ) -0-α-D-glucuronic acid ( cyclomaltoheptaosyl- ( 6 -1 ) -O-α-D-glucopyranosyl- ( 4 -1 ) -O-α-D- glucopyranosyl- (4-1 ) -O-α-D-glucopyranosiduronic acid) (β-CyD- G3-COOH), and their salts described above (e.g., sodium salt
of β-CyD-G2-COOH (sodium cyclomaltoheptaosyl-(6-1)-O-α-D- glucopyranosyl-(4-1)-O-α-D-glucopyranosiduronate (likewise abbreviated as β-CyD-G2-COONa) ) .
Specifically, 6-0-cyclomaltohexaosyl-(6-1)-α-D- glucosyl-(4-l)-0-α-D-glucuronic acid (α-CyD-G2-COOH) , 6-0- cyclomaltoheptaosyl-(6-1)-α-D-glucosyl-(4-1)-O-α-D-glucuronic acid ..(β-CyD-G2-C00H) and 6-0-cyclomaltooctaosyl-(6-1)-α-D- glucosyl-(4-1)-O-α-D-glucuronic acid (γ-CyD-G2-C00H) are branched cyclodextrin-carboxylic acids containing α- cyclodextrin (containing 6 glucose units), β-cyclodextrin (containing 7 glucose units) and γ-cyclodextrin (containing 8 glucose units), respectively. In each of these branched cyclodextrin-carboxylic acid, maltose is attached to one of the glucose units of the cyclodextrin ring through an α-(l-6) linkage, and the hydroxymethyl group (-CH20H) at the 6- position of the terminal glucose unit of the maltose is oxidized to a carboxyl group to give glucuronic acid.
Eachof 6-0-cyclomaltohexaosyl-(6-1)-α-D-glucuronic acid (α-CyD-Gi-COOH) , 6-0-cyclomaltoheptaosyl-(6-l)-α-D- glucuronic acid (β-CyD-G^COOH) and 6-O-cyclomaltooctaosyl- (6-1)-α-D-glucuronic acid (γ-CyD-G.-COOH) is a branched cyclodextrin-carboxylic acid in which glucose is attached to one of the glucose units of the cyclodextrin ring through an α-(l-6) linkage, and the hydroxymethyl group (-CH20H) at the
6-position of the branched glucose is oxidized to a carboxyl group to give glucuronic acid.
Further, 2-0-(6-cyclomaltohexaosyl)-acetic acid (α- CyD-CH2C00H) , 2-0-(6-cyclomaltoheptaosyl)-acetic acid (β-CyD- CH2C00H) and 2-0-(6-cyclomaltooctaosyl)-acetic acid (γ-CyD- CH2C00H) are preferable branched cyclodextrin-carboxylic acid wherein a carboxymethyl group is attached as a branch to one of the glucose units of the cyclodextrin ring.
These branched cyclodextrin-carboxylic acids or salts thereof are described in EP-A 0599646 (JP-A 7-076594) and in EP-A 0657176, and can be prepared, for example, by the methods described in the literatures.
In the present invention, the water-solubility of an antiulcerative benzimidazole compound and the stability of the compositions containing the compound can be enhanced by formulating the compound together with a branched cyclodextrin-carboxylic acid.
The antiulcerative benzimidazole compound to be used is normally a proton pump inhibitor having a water-solubility of not more than 10 mg/ml.
The term proton pump inhibitor as used herein is defined as a drug that suppresses acid secretion by directly or indirectly inhibiting H/K-ATPase, which functions as a proton pump in gastric mucosal acid secreting cells (parietal cells). Representative examples of such drugs include
omeprazole, lansoprazole, pantoprazole, pariprazole sodium, leminoprazole, TY-11345, TU-199, FPL-65372, BY-686, Tannic acid, Ellagic acid, Ebselen, AHR-9294, Cassigarol-A, Bafilomycin, Y-25942, Xanthoangelol E, SK&F-96356, (-)- Epigallocatechin gallate, Y-27198, T-330 and KF-20054.
In detail, proton pump inhibitors include benzimidazole compounds, which possess proton pump inhibitory activities and are of low toxicity. Preferable benzimidazole compounds include 2-[ (pyridyl)-methylsulfinyl or methylthio]benzimidazole derivatives and salt thereof. A compound (or salt thereof) represented by formula (I) below is more preferred.
wherein ring A may optionally be substituted; R is a hydrogen atom, an alkyl group, an acyl group, a carboalkoxy group, a carbamoyl group, an alkylcarbamoyl group, a dialkylcarbamoyl group or an alkylsulfonyl group; Rc, Rβ, and R8 are, the same or different, a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkoxy group; R is a hydrogen atom, an alkyl group or a group represented by -OR in which R represents a
hydrocarbon group which may optionally be substituted; q is 0 or 1.
Benzimidazole compounds above are described in USP 4,045,563, USP 4,255,431, USP 4,359,465, USP 4,472,409, USP 4,508,905, USP 5,039,806 (JP-A 59181277), USP 4,628,098, USP 4,738,975, USP 5,045,321, USP 4,786,505, USP 4,853,230, USP 5,045,552, EP-A-295603, USP 5,312,824, EP-A-166287, EP-A- 519365, and other publications.
With respect to formula (I) above, the substituent that may optionally be present on ring A includes halogen atoms, alkyl groups which may be substituted for, cycloalkyl groups which may be substituted for, alkenyl groups which may be substituted for, alkoxy groups which may be substituted for, cyano groups, carboxy groups, carboalkoxy groups, carboalkoxyalkyl groups, carbamoyl groups, carbamoylalkyl groups, hydroxy groups, hydroxyalkyl groups, acyl groups, carba oyloxy groups, nitro groups, acyloxy groups, aryl groups, aryloxy groups, alkylthio groups and alkylsulfinyl groups, and the like. The above substituents are hereinafter described.
Halogen atoms include fluorine, chlorine, bromine and iodine. Fluorine and chlorine are preferred, with greater preference given to fluorine.
The alkyl group in the alkyl group which may be substituted is exemplified by straight-chain or branched alkyl
groups having 1 to 10 carbon atoms (e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl) . Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms. Substituents on the substituted alkyl group include halogens, nitro, cyano groups, hydroxy groups, carboxy groups, amidino groups, guanidino groups, carbamoyl groups, amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.
The cycloalkyl group in the cycloalkyl group which may be substituted is exemplified by cycloalkyl groups having 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, etc. The cycloalkyl group may be substituted by, for example, halogens, nitro, cyano groups, hydroxy groups, carboxy groups, amidino groups, guanidino groups, carbamoyl groups, amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like.
The alkenyl group in the alkenyl group which may be substituted is exemplified by straight-chain or branched alkenyl groups having 2 to 16 carbon atoms. Such alkenyl groups include allyl, vinyl, crotyl, 2-penten-l-yl, 3-penten- 1-yl, 2-hexen-l-yl, 3-hexen-l-yl, 2-methyl-2-propen-l-yl and
3-methyl-2-buten-l-yl. Straight-chain or branched alkenyl groups having 2 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkenyl groups having 2 to 4 carbon atoms. The alkenyl group may be substituted by, for example, halogens, nitro, cyano groups, amidino groups, guanidino groups amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like. The alkenyl group mentioned above includes isomers (E- and Z-configurations) with respect to double bond. The alkoxy group in the alkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 10 carbon atoms. Such alkoxy groups include methoxy, ethoxy, n- propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert- butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, cyclobutoxy, cyclopentoxy and cyclohexyloxy. Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms. The alkoxy group may be substituted by, for example, halogens, nitro, amidino groups, guanidino groups amino groups which may have 1 to 2 alkyl groups, acyl groups or other substituents, and the like
The halogen as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is exemplified by chlorine, bromine, fluorine and iodine.
The alkyl group in the alkylamino group as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is preferably exemplified by straight-chain or branched alkyl groups having 1 to 6 carbon atoms. Such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, isopentyl, n-hexyl and isohexyl. Among other, straight-chain or branched alkyl groups having 1 to 4 carbon atoms are preferred.
The acyl group in the acylamino group as a substituent on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is exemplified by acyl groups derived from organic carboxylic acids, with preference given to alkanoyl groups having 1 to 6 carbon atoms. Such alkanoyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl, with greater preference given to alkanoyl groups having 1 to 4 carbon atoms.
The number of substituents on the above-described alkyl, cycloalkyl, alkenyl or alkoxy group is 1 to 6, preferably 1 to 3.
The substituted alkyl groups include trifluoro- ethyl, trifluoroethyl, difluoromethyl, trichloromethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxyethyl, ethoxyethy, 1-methoxyethyl, 2-methoxyethyl, 2,2-dimethoxy- ethyl, 2,2-diethoxyethyl and 2-diethylphosphorylethyl, among
others. Difluoromethyl, trifluoromethyl and hydroxymethyl are preferred, with greater preference given to trifluoromethyl.
The substituted cycloalkyl groups include 2- aminocyclopropan-1-yl, 4-hydroxycyclopentan-l-yl and 2,2- difluorocyclopentan-1-yl, among others.
The substituted alkenyl groups include 2,2- dichlorovinyl, 3-hydroxy-2-propen-l-yl and 2-methoxyvinyl, among others.
The substituted alkoxy groups include difluoromethoxy, trifluoro ethoxy, 2,2,2-trifluoroethoxy, 2- methoxyethoxy, 4-chlorobenzyloxy and 2-(3,4-dimethoxypehnyl)- ethoxy, among others. Difluoromethoxy is preferred.
The alkoxy group in the carboalkoxy group is exemplified by alkoxy groups having 1 to 7 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxyl, heptyloxy) .
The alkoxy group in the carboalkoxyalkyl group is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy) . The alkyl group in the carboalkoxyalkyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl). Such carboalkoxyalkyl groups include carbomethoxymethyl, 2-
carbomethoxyethyl, 2-carbomethoxypropyl, carboethoxymethyl, 2-carboethoxyethyl, 1-carbomethoxypropyl, carbopropoxymethyl and carbobutoxymethyl.
The alkyl group in the carba oylalkyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert-butyl) .
The alkyl group in the hydroxyalkyl group is exemplified by alkyl groups having 1 to 7 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl) .
The acyl group as such or the acyl group in the acyloxy group is exemplified by alkanoyl groups having 1 to 4 carbon atoms such as formyl, acetyl, propionyl, butyryl and isobutyryl.
The aryl group as such or the aryl group in the aryloxy group is exemplified by aryl groups having 6 to 12 carbon atoms (e.g., phenyl, naphthyl). The alkyl in the alkylthio group or alkylsulfinyl group is exemplified by alkyl groups having 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl) .
The number of substituents on substituted ring A is preferably 1 to 4, more preferably 1 to 2. Such substituents on the benzene ring may be present at 4- and 5-positions, with preference given to 5-ρosition. Ring A is preferably a ring which may optionally be substituted by i) a halogen atom, ii) an alkyl group which may be substituted, iii) a cycloalkyl group which may be substituted, iv) an alkenyl group which may be substituted, or v) an alkoxy group which may be substituted. The alkyl group for Rb is exemplified by alkyl groups having 1 to 5 carbon atoms (e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl). The acyl group for R is exemplified by acyl groups having 1 to 4 carbon atoms, such as alkanoyl groups having 1 to 4 carbon atoms. The alkoxy in the carboalkoxy group is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., formyl, acetyl, propionyl, butyryl, isobutyryl). The alkyl in the alkylcarbamoyl group and dialkylcarbamoyl group is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl). The alkyl in the alkylsulfonyl group is exemplified by the above-mentioned alkyl groups having 1 to 4 carbon atoms. R is preferably hydrogen.
The alkyl group for Rc, Rθ or R8 is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl). Straight- chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms.
The alkoxy group for Rc, Re or R8 is exemplified by alkoxy groups having 1 to 10 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec- butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy) . Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.
The alkoxy in the alkoxyalkoxy group for Rc, Re or R8 is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy) . Rc is preferably a hydrogen atom, an alkyl group or an alkoxy group. Rβ is preferably a hydrogen atom, an alkyl group or an alkoxy group. R8 is preferably a hydrogen atom.
The alkyl group for Rd is exemplified by alkyl groups having 1 to 4 carbon atoms (e.g., methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl).
The hydrocarbon group in the hydrocarbon group which may optionally be substituted, for Rf, is exemplified by hydrocarbon groups having 1 to 13 carbon atoms, such as straight-chain or branched alkyl groups having 1 to 6 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, isopentyl, hexyl), alkenyl groups having 2 to 6 carbon atoms (e.g., vinyl, allyl, 2-butenyl, methylallyl, 3-butenyl, 2-pentenyl, 4-pentenyl, 5-hexenyl), alkynyl groups having 2 to 6 carbon atoms (e.g., ethynyl, propargyl, 2-butyn-l-yl, 3-butyn-2-yl, l-pentyn-3-yl, 3- pentyn-1-yl, 4-pentyn-2-yl, 3-hexyn-l-yl) , cycloalkyl groups having 3 to 6 carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), cycloalkenyl groups having 3 to 6 carbon atoms (e".g., cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl) , aralkyl groups having 7 to 13 carbon atoms (e.g., benzyl, 1-phenetyl, 2-phenetyl) and aryl groups having 6 to 10 carbon atoms (e.g., phenyl, naphthyl). Straight-chain or branched alkyl groups having 1 to 6 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, isopentyl, hexyl) are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 4 carbon atoms.
The substituent group in the substituted hydrocarbon group is exemplified by C6_10 aryl groups (e.g., phenyl, naphthyl), amino, Cj.β alkylamino groups (e.g., methylamino,
ethylamino, isopropylamino) , di-Cj.g alkylamino groups (e.g., dimethylamino, diethylamino) , N-aralkyl-N-cycloalkylamino groups (e.g., N-benzyl-N-cyclohexylamino) , N-aralkyl-N- alkylamino groups (e.g., N-(1-naphthylmethyl)-N-ethylamino) , azide, nitro, halogens (e.g., fluorine, chlorine, bromine, iodine), hydroxyl, C^ alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy) , C6_10 aryloxy groups (e.g., phenoxy, naphthyloxy) , Cχ_6 alkylthio groups (e.g., methylthio, ethylthio, propylthio), C6_10 arylthio groups (e.g., phenylthio, naphthylthio), cyano, carbamoyl groups, carboxyl groups, C,. alkoxycarbonyl groups (e.g., methoxycarbonyl, ethoxycarbonyl) , C7_u aryloxycarbonyl groups (e.g., phenoxycarbonyl, 1-naphthyloxycarbonyl, 2-naphthyloxy- carbonyl), carboxy-Cι_4 alkoxy groups (e.g., carboxymethoxy, 2-carboxyethoxy) , Cι.6 alkanoyl groups (e.g., formyl, acetyl, propionyl, isopropionyl, butyryl, pentanoyl, haxanoyl), C7_n alloyl groups (e.g., benzoyl, 1-naphthoyl, 2-naphthoyl) , C6_10 arylsulfonyl groups (e.g., benzenesulfonyl, 1-naphthyl- sulfonyl, 2-naphthylsulfonyl) , C^ alkylsulfinyl groups (e.g., methylsulfinyl, ethylsulfinyl) , C6_10 arylsulfinyl groups (e.g., benzenesulfinyl, 1-naphthylsulfinyl, 2-naphthyl- sulfinyl), Cim6 alkylsulfonyl groups (e.g., methylsulfonyl, ethylsufonyl) , 5- or 6-membered heterocyclic groups (e.g., 2- furyl, 2-thienyl, 4-thiazolyl, 4-imidazolyl, 4-pyridyl, 1,3,4-
thiadiazol-2-yl, l-methyl-5-tetrazolyl) containing 1 to 4 heteroatoms (e.g., nitrogen, oxygen, sulfur), 5- or 6-membered heterocyclic carbonyl groups (e.g. 2-furoyl, 2-thienoyl, nicotinoyl, isonicotinoyl) containing 1 to 4 heteroatoms (e.g., nitrogen, oxygen, sulfur), 5- or 6-membered heterocyclic thio groups (e.g., 4-pyridylthio, 2- pyrimidylthio, l,3,4-thiadiazol-2-ylthio, l-methyl-5- tetrazolylthio) containing 1 to 4 heteroatoms (e.g., nitrogen, oxygen, sulfur) . The heterocyclic thio group may condense with the benzene ring to form a bicyclic condensed thio group
(e.g., 2-benzothiazolylthio, 8-quinolylthio) . Halogens (e.g., fluorine, chlorine, bromine, iodine), hydroxyl and C^ alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy) are preferred.
The number of substituents is normally 1 to 5, preferably 1 to 3.
R is preferably an alkoxy group which may be substituted, or an alkoxyalkoxy group which may be substituted. The alkoxy in the alkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 8 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy) . The alkoxy in the alkoxyalkoxy group which may be substituted is exemplified by alkoxy groups having 1 to 4 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy,
sec-butoxy, tert-butoxy) . R is more preferably an alkoxy group having 1 to 8, preferably 1 to 4 carbon atoms, which may be halogenated, or an alkoxyalkoxy group which may be halogenated. Preferred alkoxy groups which may be halogenated include 2,2,2-trifluoroethoxy, 2,2,3,3,3-pentafluoropropoxy, 1-(trifluoromethyl)-2, 2, 2-trifluoroethox , 2,2,3,3- tetrafluoropropoxy, 2,2,3,3,4,4,4-heptafluorobutoxy, 2,2,3,3,4,4,5,5,-octafluoropentoxy and methoxy. Preferred alkoxyalkoxy groups which may be halogenated include 3- methoxypropoxy. q is preferably 0.
More specifically, the benzimidazole compound for the present invention is exemplified by a compound represented by formula (II) :
wherein ring A may optionally be substituted; R , R and R are, the same or different, hydrogen, or an alkyl or alkoxy group; R2 is a hydrocarbon group which may optionally be substituted; n is 0 or 1.
With respect to formula (II) above, ring A is exemplified by the same rings as those mentioned for ring A of formula (I) above.
The alkyl group for R1, R3 or RA is exemplified by straight-chain or branched alkyl groups having 1 to 10 carbon atoms. Such alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl. Straight-chain or branched alkyl groups having 1 to 6 carbon atoms are preferred, with greater preference given to straight-chain or branched alkyl groups having 1 to 3 carbon atoms.
The alkoxy group for R1, R3 or R is exemplified by alkoxy groups having 1 to 10 carbon atoms. Such alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, cyclobutoxy, cyclopentoxy and cyclohexyloxy. Alkoxy groups having 1 to 6 carbon atoms are preferred, with greater preference given to alkoxy groups having 1 to 3 carbon atoms.
The hydrocarbon group which may optionally be substituted, for R2, is exemplified by the same hydrocarbon groups as those mentioned for R above.
R1 is preferably C^ alkyl or C^ alkoxy, more preferably C^.
R is preferably hydrogen or C^ alkyl, more preferably hydrogen.
R is preferably C^ alkoxy which may optionally be substituted by i) halogen, ii) hydroxyl or iii)
alkoxy, more preferably, Cι_3 alkyl which may optionally be substituted by i) halogen or ii) Cw alkoxy.
R is preferably hydrogen.
Examples of benzimidazole compounds for the present invention include 2-[2-[3-methyl-4-(2,2,3,3-tetrafluoro- propoxy)pyridyl]methylthio]benzimidazole, 2-[2-[3-methyl-4- (2,2,2-trifluoroethoxy)pyridyl]methylsulfinyl]benzimidazole (lansoprazole) , 2-[ (2-pyridyl)methylsulfinyl]benzimidazole (timoprazole) , 2-[2-(3,5-dimethyl-4-methoxypyridyl)methyl- sulfinyl]-5-methoxy-lH-benzimidazole (omeprazole), sodium salt of 2-[2-[4-(3-methoxypropoxy)-3-methyl]pyridyl]methylsulfinyl- lH-benzimidazole and 2-[2-(3,4-dimethoxy)pyridyl]methyl- sulfinyl-5-difluoromethoxy-lH-benzimidazole (pantoprazole) .
Among others, lansoprazole and omeprazole are preferably applied to the present invention. A benzimidazole compound (or salt thereof) for the present invention is produced by, for example, the above- described known methods described in Japanese or European Patent Publications and U.S. Patents, or modifications thereof.
The salt of a benzimidazole compound is preferably used as a physiologically acceptable salt. Physiologically acceptable salts include salts with inorganic bases, salts with organic bases and salts with basic amino acids. Useful inorganic bases include alkali metals (e.g., sodium, potassium) and alkaline earth metals (e.g., calcium, magnesium). Useful organic bases include trimethylamine, triethylamine, pyridine, picoline, N,N-dibenzylethylene- diamine, ethanolamine, diethanolamine, trishydroxymethyl- aminomethane and dicyclohexylamine. Useful basic amino acids include arginine and lysine.
These salts are produced by known methods such as those described in EP-A-295603 and USP 4,738,974, or modifications thereof. In the present invention, the mixing ratio of the branched cyclodextrin-carboxylic acid to the antiulcerative benzimidazole compounds is not limited and can be selected from wide ranges. However, considering the water-solubility of the compounds, the amount of the branched cyclodextrin- carboxylic acid to be used is 0.1 to 20 mol, preferably 0.1 to 10 mol, more preferably 0.2 to 5 mol, particularly preferably 2 to 5 mol, per mol of the antiulcerative benzimidazole compound.
The composition of the present invention can be prepared by mixing the branched cyclodextrin-carboxylic acid
with the antiulcerative benzimidazole compound according to known methods. Roughly speaking, the inclusion compound of the antiulcerative benzimidazole compound included in the branched cyclodextrin-carboxylic acid can be prepared, for example, by the following four methods:
(1) Co-precipitation method (Crassons, et al., 5th Int. Conf. Pharmaceutical Technology, Paris, May 30 to June 1, 1989),
(2) Lyophilizing or spray drying method (Kurozumi et al., Chem. Pharm. Bull., 23, 3062 (1975); Kata et al.,
Pharmazie 39, 856 (1984)),
(3) Phase - solubility curve crystallization method (Uekama et al.. Int. J. Pharm. 10,1 (1982)),
(4) Milling method (J. Szejtli et al., "Cyclodextrins and their inclusion complexes", Akadeimial
Kiado, Budapest (1982), p. 109-114; Kyowa Jap. Prov. Pat. Pubin. No. 106 698 (1982)).
Specifically, the inclusion compound can be prepared as follows: (1) A compound to be included in the inclusion compound is added to an aqueous solution of the branched cyclodextrin-carboxylic acid (hereinafter sometimes referred to as the cyclodextrin). The mixture is stirred (shaken), if necessary, under warming. The remaining unreacted compound
to be included is removed by filtration, centrifugation, etc., to obtain an inclusion compound.
(2) The cyclodextrin is dissolved in water, and a compound to be included is added thereto. The two are mixed for 10 minutes to several hours, followed by lyophilization (M. Kurozumi et al., Chem. Pharm. Bull., 23, 142 (1975)) to give powder. This powder is dissolved in water, and the unreacted compound to be included is removed to obtain an aqueous solution of an inclusion compound. (3) A compound to be included is dissolved in an appropriate water-soluble organic solvent in advance. This solution is contacted with cyclodextrin in an aqueous solution. Then the organic solvent and water are evaporated in vacuo or lyophilized (EP-A-519428, JP-A 5 (1992,-178765), and water is then added to the residue to dissolve it, and the unreacted compound to be included is removed to obtain an aqueous solution of an inclusion compound.
(4) When an acidic compound is included in the inclusion compound, it is dissolved in ammonia water and cyclodextrin is added thereto, and the mixture is lyophilized. During the lyophilization, excess ammonia is removed and an inclusion compound is obtained as an ammonium salt of the acidic compound.
(5) A compound to be included is dissolved in a lipophilic organic solvent (e.g., ethyl ether, etc.), and the
solution is mixed with a saturated aqueous solution of the cyclodextrin. The mixture is shaken vigorously for 10 minutes to several hours and then allowed to stand in a cold place overnight to precipitate an inclusion compound. The precipitate is separated by centrifugation or filtration. The resulting powder is dissolved in water to give an aqueous solution of an inclusion compound.
(6) A powdered compound to be included and powdered cyclodextrin are mixed, and a small amount of water is added thereto. The mixture is kneaded (Y. Nakai et al., Chem. Pharm. Bull., 26, 2419 (1978)) and then, if necessary, lyophilized.
(7) An aqueous solution of the cyclodextrin and an aqueous solution of a compound to be included are mixed to give an aqueous solution of an inclusion compound.
In particular, the above method (3) is useful for solubilization of antiulcerative benzimidazole compounds.
In many cases, the aqueous solution or powder thus obtained by the known methods giving inclusion compounds contains an inclusion compound or a complex formed by electrostatic or hydrophobic interactions or hydrogen bonds, etc. Therefore, the term "inclusion compound" used in the present invention means not only an inclusion compound or a complex per se but also a mixture of an inclusion compound, a complex, a free compound to be included and/or a free
cyclodextrin. That is, the powder and aqueous solution obtained may contain, other than an inclusion compound or a complex, a water-insoluble or slightly water-soluble compound that is not included or complexed, and/or free cyclodextrin. The inclusion compound per se and powder and an aqueous solution like this have extremely high water-solubilities and dissolve in water instantly.
The composition of the present invention may be the aqueous solution or powder per se thus obtained, or it may be a pharmaceutical composition in an appropriate dosage form, a veterinary composition, etc. , prepared using known additives such as excipients, binders or lubricants.
For example, to improve properties of the powder obtained above (packing capacity into a storage bottle or a vial, specific volume, destaticizing, etc.), saccharides, antiseptics, stabilizers, antistatic agents, etc., can be added. For example, when injections are prepared, the powder obtained by this operation readily dissolves in an aqueous isotonic solution prepared using distilled water or sodium chloride and saccharides (e.g., glucose, mannitol, inositol, etc.). After dissolution, the resulting injectable preparation containing an active ingredient can be administered intravenously, intramuscularly, subcutaneously, into organs, or directly to foci such as tumor or excised parts of tumor, in a drug concentration effective in vivo
against the diseases to be treated. When oral preparations are prepared, tablets, capsules, granules, fine granules, enveloped preparations, drops, liquids, etc., can be prepared. On formulating these preparations, known excipients, lubricants, binders, dispersers, stabilizers, colorants and absorption-improving (promoting) agents, etc., can normally be used.
The above powder can also be formulated into preparations other than injectable or oral preparations according to conventional methods. Examples of such preparations are preparations administered to mucous membranes such as nose, the rectum. Each of the above preparations can be molded into various controlled-release preparations or preparations for targeting therapies, and the composition of the present invention can be used as a raw material of such preparations.
In the present invention, the composition is preferably an injectable composition, especially intravenously injectable solution. In terms of the stability of the composition, the composition preferably further contains a pH adjusting agent, such as meglumine, sodium hydroxide, potassium hydroxide, ammonia water, sodium bicarbonate, sodium carbonate, triethanolamine , monoethanolamine , diisopropanolamine, triisopropanolamine and L-arginine. The amount of the pH adjusting agent to be used is 0.01 to 10 mol,
preferably 0.1 to 5 mol, per mol of the antiulcerative benzimidazole compound. Preferably, the composition is miscible with a transfusion solution, and can be used as a mixture of the composition and a transfusion solution. Any commercially available or conventional transfusion solution can be used. Examples of the transfusion solution include glucose injection, xylitol injection, D-mannitol injection, fructose injection, isotonic sodium chloride solution, dextran 40 injection, dextran 70 injection, amino acid injection, Ringer's injection, lactated Ringer's injection. The ratio of the composition to the transfusion solution is 1/1 (v/v) to 1/500 (v/v), preferably 1/20 (v/v) to 1/100 (v/v).
As described above, the branched cyclodextrin- carboxylic acid used in the present invention enhances the water-solubility of antiulcerative benzimidazole compounds and has high safety to the living body. Therefore, the composition of the present invention is applicable to the prevention and treatment of animal ulcers, and is particularly effective in the prevention and treatment of digestive ulcers in mammals (e.g., humans, monkeys, cattle, dogs, swine, etc.). Examples of such digestive ulcers include gastric ulcer, duodenal ulcer, reflux esophagitis, anastomotic ulcer, acute and chronic gastritis. Specifically, for example, the composition comprising lansoprazole as the antiulcerative benzimidazole compound can be used in accordance with the
manner described in EP 0174726. The composition of the present invention can be administered in an appropriate dosage form such as injections, oralpreparations, syrups, preparations externally administered to skin, pernasal preparations, rectal suppositories or preparations applied to mucous membranes.
Although the dose of the composition of the present invention is chosen as appropriate, according to ulcer type, symptoms, age and the other factors, for example, in the case of the compositions of proton pump inhibitors, the compositions are administered at the dose of 0.01 mg/kg/day -
50 mg/kg/day, preferably 0.1 - 3 mg/kg/day, more preferably
0.1 - 1 mg/kg/day, as the dose of the proton pump inhibitors.
Specifically, in the case of the composition of lansoprazole, the daily dose of lansoprazole is 0.01 - 30 mg/kg, more preferably 0.1 - 3 mg/kg.
The following examples further illustrate the present invention in detail, but are not to be construed to limit the scope thereof. Example 1
Lansoprazole [ (+)-2-[ [ [3-methyl-4-(2,2,2-trifluoro¬ ethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole] (19 mg) was dissolved in methanol (10 ml) . Separately from this solution, sodium 6-0-cyclomatoheptaosyl-(6-l)-α-D-glucosyl-(4-1)-0-α- D-glucuronate (β-CyD-G2-C00Na) (384 mg) was dissolved in water
(10 ml). The aqueous solution was added to the methanol solution with stirring, and the mixture was stirred for 30 seconds. The solvent in the resulting solution was evaporated under reduced pressure. The residue was dissolved in water (2 ml) , and the solution was filtered through a membrane filter (0.22 μm) .
Separately, lansoprazole alone was added to water. The mixture was shaken at room temperature, and filtered through a membrane filter (0.22 μm) . The lansoprazole in the above homogeneous aqueous solution and filtrate was determined by high performance liquid chromatography (HPLC) . HPLC conditions:
Column : YMC AQ-312, 6 μm x 15 cm Mobile phase : H20:CH3CN:triethylamine = 60:40:1
(pH 7.0) Flow rate : 1 ml/min Temperature : Room temperature Detection : UV 285 nm The results are as follows.
Comparison of the water-solubilitv of the antiulcerative compound
Lansoprazole combined with β-CyD-G2-COONa 0.892 mg/ml Lansoprazole alone 0.007 mg/ml
The results show that addition of β-CyD-G2-COONa remarkably increased the water-solubility of the antiulcerative compound compared with the case in which the antiulcerative compound was used alone. Example 2
Lansoprazole [ (±)-2-[ [ [3-methyl-4-(2,2,2-trifluoro¬ ethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole] (19 mg) was dissolved in methanol (5 ml). Separately from this solution, sodium 6-0-cyclomatoheptaosyl-(6-1)-α-D-glucosyl-(4-1)-0-α- D-glucuronate (β-CyD-G2-C00Na) (384 mg) was dissolved in water (5 ml). The aqueous solution was added to the methanol solution with stirring, and the mixture was stirred for 30 seconds. The solvent in the resulting solution was evaporated under reduced pressure. The residue was dissolved in water (10 ml), and the solution was filtered through a membrane filter (0.22 μm) and lyophilized to obtain powder. The powder (200 mg) was completely dissolved in water (200 ml).
The lyophilized composition comprising β-CyD-G2- COONa and lansoprazole of the present invention was an inclusion compound which was stable at room temperature without decomposition of the lansoprazole. Example 3
Lansoprazole [ (±)-2-[ [[3-methyl-4-(2,2,2-trifluoro- ethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole] (300 mg) was dissolved in ethanol (50 ml). Separately from this solution.
sodium 6-0-cyclomatoheptaosyl-(6-1)-α-D-glucosyl-(4-1)-0-α- D-glucuronate (β-CyD-G2-COONa) (6.05 g) and meglumine (1-deoxy- l-(methylamino)-D-glucitol) (600 mg) were dissolved in water (50 ml). The pH of the solution was adjusted to 11.5 with IN NaOH. The ethanol solution was added to the aqueous solution with stirring, and the mixture was stirred for 60 seconds. The solvent in the resulting solution was evaporated under reduced pressure. The residue was dissolved in water (50 ml), and the solution was filtered through a membrane filter (0.22 μm) and lyophilized to obtain powder. The lansoprazole content in the resulting powder was 3.78% (w/w) , and the water content in the powder was 10.9%. Example 4 The lyophilized powder obtained in Example 3 was filled into vials (150 mg powder per vial) and dried over phosphorus pentaoxide, and each vial was sealed under an atmosphere of nitrogen gas. A preparative stability test was carried out at 40°C for 4 weeks. The water content was 0.5% after drying over phosphorus pentaoxide, and the amount of the residual lansoprazole was not less than 95% after 4 weeks.
Example 5
The lyophilized powder obtained in Example 3 was dissolved in water for injection (150 mg powder per ml of the water for injection). The solution was mixed with isotonic sodium chloride solution (Otsuka Seishoku Chu (Otsuka
Pharmaceutical Co., Ltd.)), glucose injection (Ohtsuka Toeki 5% (Otsuka Pharmaceutical Co., Ltd.)), Ringer's solution containing low molecular weight dextran and lactic acid (Low Molecular Weight Dextran L Injection (Otsuka Pharmaceutical Co., Ltd.)) and an electrolyte solution for transfusion (Solita T No. 3 (Shimizu Pharmaceutical Co., Ltd.)). The stability of lansoprazole after the addition of transfusion solution was tested. The composition ratio of the aqueous lyophilized powder solution to the transfusion solution was 1/99 (v/v) . The amount of the residual lansoprazole was not less than 98% in the isotonic sodium chloride solution and glucose injection until 8 hours after the addition, not less than 97% in the Ringer's solution until 4 hours after the addition, and not less than 93% in the electrolyte solution for transfusion until 4 hours after the addition.
Example 6
The lyophilized powder obtained in Example 3 was dissolved in water for injection (150 mg powder per ml of the water for injection). The solution was added to each of Ringer's solution containing low molecular weight dextran and lactic acid (Low Molecular Weight Dextran L Injection (Otsuka Pharmaceutical Co., Ltd.)) and an electrolyte solution for transfusion (Solita T No. 3 (Shimizu Pharmaceutical Co., Ltd.)). The stability of lansoprazole after the addition of the transfusion solution was compared with that in a
formulation containing no cyclodextrin-carboxylic acid [the formulation being a solution of lyophilized powder of lansoprazole (30 mg) containing mannitol (60 mg) and meglu ine (10 mg) in an aqueous 30% polyethylene glycol 400 solution (5 rol)]- Tne composition ratio of the aqueous lyophilized powder solution to the transfusion solution was 1/99 (v/v) . The composition ratio of the formulation containing no cyclodextrin-carboxylic acid to the transfusion solution was 1/99 (v/v). The amounts of the lansoprazole remaining 1 hour,
4 hours and 18 hours after the addition of the Ringer's solution containing low molecular weight dextran and lactic acid were 98.9%, 97.7% and 91.0%, respectively, in the case of the composition of Example 3, compared with 80.1%, 45.6% and 4.4%, respectively, in the case of the formulation containing no cyclodextrin-carboxylic acid.
The amounts of the lansoprazole remaining 1 hour, 4 hours and 18 hours after the addition of the electrolyte solution for transfusion were 98.2%, 93.3% and 62.3%, respectively, in the case of the composition of Example 3, compared with 60.1%, 12.8% and 0%, respectively, in the case of the formulation containing no cyclodextrin-carboxylic acid.
As described above, the composition of the present invention is very stable, and the antiulcerative benzimidazole compound combined with a branched cyclodextrin-carboxylic acid
according to the present invention has a much higher water- solubility compared with that of the antiulcerative benzimidazole compound alone. In addition, the branched cyclodextrin-carboxylic acid has less effect (e.g., destruction of erythrocytes) on the living body than β- cyclodextrin, and therefore is highly safe for blood. Moreover, β-CyD-G2-COOH is hardly decomposed with acids or enzymes, and therefore the composition of the present invention is highly safe to mammals including humans.
Claims
1. A stabilized composition comprising an antiulcerative benzimidazole compound and a branched cyclodextrin-carboxylic acid or a salt thereof.
2. A composition according to claim 1, wherein the antiulcerative benzimidazole compound is a proton pump inhibitor.
3. A composition according to claim 1, wherein the amount of the branched cyclodextrin-carboxylic acid is 0.1 to 20 mol per mol of the antiulcerative benzimidazole compound.
4. A composition according to claim 1, wherein the branched cyclodextrin-carboxylic acid is a cyclodextrin having an organic group containing at least one carboxyl group at the 6-O-position of at least one glucose unit of the cyclodextrin ring.
5. A composition according to claim 4, wherein the cyclodextrin ring has 7 glucose units.
6. A composition according to claim 4, wherein the organic group has 1 to 3 glucose units and at least one of the hydroxymethyl groups of the glucose unit(s) in the organic group is oxidized to a carboxyl group.
7. A composition according to claim 4, wherein the organic group is 2-carboxyethyl or 2-carboxy-2-hydroxyethyl.
8. A composition according to claim 1, wherein the branched cyclodextrin-carboxylic acid is 6-0-cyclomalto- hexaosyl-(6-1)-α-D-glucosyl-(4-1)-O-α-D-glucuronicacid, 6-0- cyclomaltoheptaosyl-(6-1)-α-D-glucosyl-(4-1)-O-α-D-glucuronic acid, 6-0-cyclomaltooctaosyl-(6-1)-α-D-glucosyl-(4-1)-O-α-D- glucuronic acid, 6-0-cyclomaltohexaosyl-(6-1)-α-D-glucuronic acid, 6-0-cyclomaltoheptaosyl-(6-1)-α-D-glucuronic acid, 6-0- cyclomaltooctaosyl-(6-1)-α-D-glucuronic acid, 2-0-(6- cyclomaltohexaosyl)-aceticacid, 2-0-(6-cyclomaltoheptaosyl)- acetic acid, 2-0-(6-cyclomaltooctaosyl)-acetic acid, 3-0-(6- cyclomaltoheptaosyl)-propionic acid, 2-hydroxy-3-0-(6- cyclomaltoheptaosyl)-propionic acid, 7 ,7 -di-0-[α-D- glucuronyl-(l-4)-0-α-D-glucosyl]-(l-6)-maltoheptaose, or 6- O-cyclomaltoheptaosyl-0-α-D-maltosyl-(4-1)-O-α-D-glucuronic acid.
9. A composition according to claim 1, wherein the branched cyclodextrin-carboxylic acid is 6-0-cyclomalto- heptaosyl-(6-1)-α-D-glucosyl-(4-1)-O-α-D-glucuronic acid.
10. A composition according to claim 1, which is a pharmaceutical composition.
11. A composition according to claim 1, which is an antiulcerative composition.
12. A composition according to claim 1, wherein the antiulcerative benzimidazole compound is represented by the formula (I) :
wherein ring A may optionally be substituted; Rb is a hydrogen atom, an alkyl group, an acyl group, a carboalkoxy group, a carbamoyl group, an alkylcarbamoyl group, a dialkylcarbamoyl group or an alkylsulfonyl group; Rc, Rβ, and R8 are, the same or different, a hydrogen atom, an alkyl group, an alkoxy group or an alkoxyalkoxy group; Rd is a hydrogen atom, an alkyl group or a group represented by -OR in which R represents a hydrocarbon group which may optionally be substituted; q is 0 or 1.
13. A composition according to claim 1, wherein the antiulcerative benzimidazole compound is lansoprazole or omeprazole.
14. A composition according to claim 1, which further comprises a pH adjusting agent.
15. A composition according to claim 14, wherein the amount of the pH adjusting agent is 0.01 to 10 mol per mol of the antiulcerative benzimidazole compound.
16. A composition according to claim 1, wherein the pH adjusting agent is meglumine.
17. A composition according to claim 1, which is for injection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU57806/96A AU5780696A (en) | 1995-06-02 | 1996-05-28 | Stabilized composition comprising an antiulcerative benzimid azole |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13681695 | 1995-06-02 | ||
JP7/136816 | 1995-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996038175A1 true WO1996038175A1 (en) | 1996-12-05 |
Family
ID=15184182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/001427 WO1996038175A1 (en) | 1995-06-02 | 1996-05-28 | Stabilized composition comprising an antiulcerative benzimidazole |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5780696A (en) |
WO (1) | WO1996038175A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040069A3 (en) * | 1997-03-13 | 1998-12-17 | Hexal Ag | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
EP1018340A1 (en) * | 1999-01-06 | 2000-07-12 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them |
US6147103A (en) * | 1998-08-11 | 2000-11-14 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
WO2002055076A1 (en) * | 2001-01-04 | 2002-07-18 | Daiichi Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical preparation |
WO2002098423A1 (en) * | 2001-06-06 | 2002-12-12 | Cipla Limited | S-omeprazole (esomeprazole) inclusion complex with cyclodextrins |
US6576258B1 (en) | 1997-07-14 | 2003-06-10 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Pharmaceutical formulation with controlled release of active substances |
WO2003059393A1 (en) * | 2002-01-15 | 2003-07-24 | Altana Pharma Ag | Pantoprazole cyclodextrin inclusion complexes |
US6780882B2 (en) | 1996-01-04 | 2004-08-24 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
WO2004093875A1 (en) * | 2003-04-22 | 2004-11-04 | Dr. Reddy's Laboratories Limited | Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these |
US6951885B2 (en) | 2000-08-10 | 2005-10-04 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
US6989381B2 (en) | 2000-08-22 | 2006-01-24 | Pharmacia Corporation | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
WO2006082490A1 (en) * | 2005-02-02 | 2006-08-10 | Ranbaxy Laboratories Limited | Injectable formulations of benzimidazole compounds |
EP1903039A4 (en) * | 2005-06-13 | 2010-09-22 | Takeda Pharmaceutical | INJECTION PRODUCT |
RU2481830C2 (en) * | 2007-01-16 | 2013-05-20 | Бипар Сайенсиз, Инк. | Medications for cancer treatment |
USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3427785A1 (en) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inclusion compounds of benzimidazole derivatives with cyclodextrins, the preparation thereof, and medicaments |
DE3427786A1 (en) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inclusion complexes of benzimidazole derivatives with cyclodextrins, the preparation thereof, and medicaments |
WO1986000913A1 (en) * | 1984-07-27 | 1986-02-13 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft M | New active substance complexes |
WO1993013138A1 (en) * | 1991-12-31 | 1993-07-08 | Sunkyong Industries Co., Ltd. | A method for preparing enteric-coated oral drugs containing acid-unstable compounds |
WO1995007263A1 (en) * | 1993-09-09 | 1995-03-16 | Schering Aktiengesellschaft | 1,2-di(hetero)arylbenzimidazole derivatives, their preparation and their use as prostacyclin (pgi2) mimetics |
EP0657176A2 (en) * | 1993-12-06 | 1995-06-14 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
-
1996
- 1996-05-28 AU AU57806/96A patent/AU5780696A/en not_active Abandoned
- 1996-05-28 WO PCT/JP1996/001427 patent/WO1996038175A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3427785A1 (en) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inclusion compounds of benzimidazole derivatives with cyclodextrins, the preparation thereof, and medicaments |
DE3427786A1 (en) * | 1984-07-27 | 1986-01-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Inclusion complexes of benzimidazole derivatives with cyclodextrins, the preparation thereof, and medicaments |
WO1986000913A1 (en) * | 1984-07-27 | 1986-02-13 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft M | New active substance complexes |
WO1993013138A1 (en) * | 1991-12-31 | 1993-07-08 | Sunkyong Industries Co., Ltd. | A method for preparing enteric-coated oral drugs containing acid-unstable compounds |
WO1995007263A1 (en) * | 1993-09-09 | 1995-03-16 | Schering Aktiengesellschaft | 1,2-di(hetero)arylbenzimidazole derivatives, their preparation and their use as prostacyclin (pgi2) mimetics |
EP0657176A2 (en) * | 1993-12-06 | 1995-06-14 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6780882B2 (en) | 1996-01-04 | 2004-08-24 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6248758B1 (en) * | 1997-03-13 | 2001-06-19 | Hexal Ag | Pharmaceutical antacid |
WO1998040069A3 (en) * | 1997-03-13 | 1998-12-17 | Hexal Ag | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
US6576258B1 (en) | 1997-07-14 | 2003-06-10 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Pharmaceutical formulation with controlled release of active substances |
US6147103A (en) * | 1998-08-11 | 2000-11-14 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
EP1018340A1 (en) * | 1999-01-06 | 2000-07-12 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them |
US7247653B2 (en) | 2000-08-10 | 2007-07-24 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
US6951885B2 (en) | 2000-08-10 | 2005-10-04 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
US6989381B2 (en) | 2000-08-22 | 2006-01-24 | Pharmacia Corporation | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
WO2002055076A1 (en) * | 2001-01-04 | 2002-07-18 | Daiichi Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical preparation |
EP1348432A4 (en) * | 2001-01-04 | 2005-08-10 | Daiichi Seiyaku Co | Cyclodextrin-containing pharmaceutical preparation |
WO2002098423A1 (en) * | 2001-06-06 | 2002-12-12 | Cipla Limited | S-omeprazole (esomeprazole) inclusion complex with cyclodextrins |
WO2003059393A1 (en) * | 2002-01-15 | 2003-07-24 | Altana Pharma Ag | Pantoprazole cyclodextrin inclusion complexes |
WO2004093875A1 (en) * | 2003-04-22 | 2004-11-04 | Dr. Reddy's Laboratories Limited | Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2006082490A1 (en) * | 2005-02-02 | 2006-08-10 | Ranbaxy Laboratories Limited | Injectable formulations of benzimidazole compounds |
EP1903039A4 (en) * | 2005-06-13 | 2010-09-22 | Takeda Pharmaceutical | INJECTION PRODUCT |
RU2481830C2 (en) * | 2007-01-16 | 2013-05-20 | Бипар Сайенсиз, Инк. | Medications for cancer treatment |
Also Published As
Publication number | Publication date |
---|---|
AU5780696A (en) | 1996-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5536735A (en) | Pharmaceutical composition | |
WO1996038175A1 (en) | Stabilized composition comprising an antiulcerative benzimidazole | |
CA2071623C (en) | Cyclodextrin composition | |
CA2111560A1 (en) | Stable pharmaceutical composition of fumagillol derivatives | |
KR101767689B1 (en) | Antimicrobiral compositions | |
JPH07316052A (en) | Composition for intrarectal administration | |
EP0555693A1 (en) | Method of producing highly watersoluble cyclodextrin complex | |
JPWO2006134877A1 (en) | Injection | |
KR100720886B1 (en) | Cilostazol Aqueous Formulations for Injection | |
JP3176716B2 (en) | Poorly water-soluble drug composition having improved solubility | |
WO2001041757A1 (en) | Cyclodextrin-containing pharmaceutical composition | |
WO2006082490A1 (en) | Injectable formulations of benzimidazole compounds | |
PL199868B1 (en) | H⁺ , K⁺-ATPase inhibitor stable liquid preparation, method for its manufacture, application of polyethylene glycol and sodium or potassium salt of H⁺ , K⁺-ATPase as well as application of this preparation | |
EP1018340A9 (en) | Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them | |
JP5113323B2 (en) | Injectable pharmaceutical composition comprising diclofenac sodium and β-cyclodextrin | |
KR20190005674A (en) | Composition for injection | |
JP3954115B2 (en) | Injection and injection kit | |
JPH0948730A (en) | Stabilizer composition containing benzimidazole-based anti-ulcer agent having improved water solubility | |
CN118574603A (en) | Injection preparation containing isoxazoline derivative and preparation method thereof | |
JPH07157440A (en) | Composition for medicine | |
US20050171057A1 (en) | Pantoprazole cyclodextrin inclusion complexes | |
JP3859742B2 (en) | Liver disease treatment | |
KR20240121186A (en) | Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition | |
JPH08291075A (en) | Cancer metastasis inhibitor | |
CN118510496A (en) | Injection preparation containing isoxazoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |